The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy

Witjes, 2021, European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines, Eur Urol, 79, 82, 10.1016/j.eururo.2020.03.055 D’Andrea, 2021, Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer, World J Urol, 39, 4345, 10.1007/s00345-021-03793-4 D’Andrea, 2020, Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer, Urol Oncol, 38, 639.e1, 10.1016/j.urolonc.2020.01.010 Stangl-Kremser, 2018, Sarcopenia as a predictive factor for response to upfront cisplatin-based chemotherapy in patients with muscle-invasive urothelial bladder cancer, Urol Int, 101, 197, 10.1159/000489013 Gild, 2020, Surg Oncol, 34, 312, 10.1016/j.suronc.2020.06.006 Seiler, 2017, Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy, Eur Urol, 72, 544, 10.1016/j.eururo.2017.03.030 Choi, 2014, Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy, Cancer Cell, 25, 152, 10.1016/j.ccr.2014.01.009 Pones, 2021, Differential prognosis and response of denovo vs. secondary muscle-invasive bladder cancer: an updated systematic review and meta-analysis, Cancers, 13, 2496, 10.3390/cancers13102496 Pietzak, 2018, Genomic differences between “primary” and “secondary” muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy, Eur Urol, 75, 231, 10.1016/j.eururo.2018.09.002 Moschini, 2016, Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy, BJU Int, 117, 604, 10.1111/bju.13146 Zargar, 2016, Final pathological stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer—does pT0 predict better survival than pTa/Tis/T1?, J Urol, 195, 886, 10.1016/j.juro.2015.10.133 Plimack, 2015, Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer, Eur Urol, 68, 959, 10.1016/j.eururo.2015.07.009 Allen, 2014, Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma, Cancer Discov, 4, 1140, 10.1158/2159-8290.CD-14-0623 Liu, 2016, Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma, JAMA Oncol, 2, 1094, 10.1001/jamaoncol.2016.1056 Yin, 2016, Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis, Oncol, 21, 708, 10.1634/theoncologist.2015-0440 Soria, 2019, Molecular markers in bladder cancer, World J Urol, 37, 31, 10.1007/s00345-018-2503-4 Moschini, 2017, Characteristics and clinical significance of histological variants of bladder cancer, Nat Rev Urol, 14, 651, 10.1038/nrurol.2017.125 Soria, 2021, Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis, BJU Int, 128, 79, 10.1111/bju.15289 de Vries, 2010, Survival after cystectomy for invasive bladder cancer, Eur J Surg Oncol, 36, 292, 10.1016/j.ejso.2009.11.012 Breau, 2014, Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis, BJU Int, 113, 900, 10.1111/bju.12403 Schrier, 2004, Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy, Eur Urol, 45, 292, 10.1016/j.eururo.2003.10.006 Kotb, 2012, Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes?, World J Urol, 30, 761, 10.1007/s00345-012-0832-2 Kayama, 2018, History of non–muscle-invasive bladder cancer may have a worse prognostic impact in cT2–4aN0M0 bladder cancer patients treated with radical cystectomy, Clin Genitourin Cancer, 16, e969, 10.1016/j.clgc.2018.04.004 Faba, 2011, Clinical predictive factors of poor outcome in patients with stage pT0 disease at radical cystectomy, J Urol, 186, 442, 10.1016/j.juro.2011.03.134 Li, 2019, ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer, Clin Cancer Res, 25, 977, 10.1158/1078-0432.CCR-18-1001